ONE Bio Corp (ONBI) Fair Value & Analysis
Healthcare · US · Market cap $10.0K
ONE Bio Corp
ONBI · US
Fair value as of: Jun 26, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $6.71 to $0.0005 (−100.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0002 – $0.0005 · fair‑value band $0.0005 – $0.0005 · the $0.0005 price screens below the $0.0005 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ONE Bio Corp (ONBI) currently trades at $0.0005, while our model-based Fair Value estimate is $0.0005 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, ONE Bio Corp generated revenue of $53.9M at a net margin of 16.6%. Revenue grew 0.3% year over year. It earns a return on equity of 20.1%. Net debt stands at $9.0M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical …
Revenue & earnings trend
FY2006 – FY2010 · reported fiscal years
ONE Bio Corp reported revenue of $52.3M in FY2010 versus $208K in FY2006, a compound +298.4%/yr. Reported net income was $8.7M in FY2010.
Is ONBI fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ONE Bio Corp (ONBI) undervalued?
What is the fair value of ONBI?
What is the quality score of ONBI?
What is the revenue of ONE Bio Corp (ONBI)?
What is the net profit margin of ONBI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.